Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Clinical trial NCT04624711 · UNKNOWN
Trial details
- NCT number
- NCT04624711
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2022-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.